Calquence, manufactured by AstraZeneca, is a targeted therapy used to treat certain types of non-Hodgkin lymphoma. The cost of Calquence can vary significantly depending on factors such as insurance coverage, pharmacy, and dosage.
How much does a monthly supply of Calquence typically cost?
Without insurance, a one-month supply of Calquence (acalabrutinib) can range from approximately $9,000 to over $15,000. This price reflects the drug's status as a specialty medication.
What does Calquence's price mean for insured patients?
For patients with commercial insurance, out-of-pocket costs are often reduced through co-pay assistance programs offered by AstraZeneca. These programs can potentially lower monthly costs to as little as $10 for eligible individuals. However, coverage limitations and plan specifics will ultimately determine the patient's financial responsibility. Medicare and Medicaid coverage also apply, with costs varying by specific plan benefits and patient eligibility.
How does Calquence's cost compare to other lymphoma treatments?
Calquence is considered a high-cost medication, consistent with many targeted therapies and immunotherapies used in oncology. Its price is influenced by the research and development expenses, clinical trial costs, and manufacturing complexities associated with novel cancer drugs. Comparisons to other treatments for chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) would require analyzing specific drug prices, dosages, and treatment durations, which can vary.
When does Calquence's patent protection expire?
Information regarding the specific patent expiry dates for Calquence is available through specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceutical products, which can provide details on when market exclusivity is expected to end [1].
What are the options for more affordable Calquence?
Beyond insurance and manufacturer co-pay programs, no generic version of Calquence is currently available due to its patent protection. Patients seeking financial assistance may explore options like the AstraZeneca Patient Assistance Program, which aims to help eligible uninsured or underinsured patients afford their medications.
What clinical data supports Calquence's use?
Calquence has demonstrated efficacy in clinical trials for both treatment-naïve and relapsed/refractory patients with CLL and MCL. Key trial data, such as that from the ELEVATE-RR study, has shown improved progression-free survival and comparable overall response rates when compared to other established therapies in specific patient populations [2].
Sources:
1. https://drugpatentwatch.com/
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9320065/